Neurim Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Neurim Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Neurim Pharmaceuticals: 6 sponsored US clinical trials, none currently recruiting.

Neurim Pharmaceuticals sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-24 Hour Sleep-Wake Disorder, with 1 trials.

Upper-quartile sponsor footprint

Neurim Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

NCT05267535
COMPLETED Phase 2

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

NCT02615002
COMPLETED Phase 3

Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

NCT01906866
COMPLETED Phase 2

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

NCT01489969
COMPLETED Phase 2

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

NCT00940589
COMPLETED Phase 2

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

NCT00972075

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 1

Therapeutic Areas

Non-24 Hour Sleep-Wake Disorder 1
Alzheimers Disease 1
Blindness 1

How the Neurim Pharmaceuticals early-phase archive is shaped

6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).

Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Non-24 Hour Sleep-Wake Disorder (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Neurim Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Neurim Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Neurim Pharmaceuticals23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Neurim Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Neurim Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Neurim Pharmaceuticals page

6 registered trials is a research-attention snapshot, not an endorsement of Neurim Pharmaceuticals or any single study.

  • None of Neurim Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Non-24 Hour Sleep-Wake Disorder is the condition Neurim Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-24 Hour Sleep-Wake Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Neurim Pharmaceuticals pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.